Biodefense Breaking News: Aethlon Medical's (OTCBB: AEMD) Hemopurifier® Used in
Successful Treatment of Patient with Advanced Ebola Infection
242 Million
Copies of Ebola Virus Removed from Patient during Treatment, Physician Reports
at American Society of Nephrology Annual Meeting
SAN DIEGO and PHILADELPHIA - November 14, 2014
(Investorideas.com newswire) The Aethlon Hemopurifier® was used in the
successful treatment of a critically-ill Ebola-infected patient in Frankfurt,
Germany, according to data presented today at the American Society of
Nephrology (ASN) Annual Meeting by Helmut Geiger, M.D., Chief of Nephrology
at Goethe University, Frankfurt University Hospital. Geiger reported that 242
million Ebola viruses were captured within the Aethlon Hemopurifier® during
treatment, a number verified by a post-treatment elution protocol. The patient
is no longer infected with Ebola virus and is expected to make a full recovery.
Aethlon
Medical, Inc. (OTCBB:AEMD), the pioneer in
developing targeted therapeutic devices to treat infectious disease, created
the Hemopurifier®, a first-in-class bio-filtration device that targets the
rapid elimination of viruses and immunosuppressive proteins from the
circulatory system of infected individuals.
The Frankfurt University Hospital patient,
a Ugandan physician, who was infected with Ebola in Sierra Leone where he was
treating Ebola patients, was not administered Hemopurifier® therapy until 12
days after being diagnosed.
At the time of Hemopurifier®
administration, Dr. Geiger reported that the Ebola patient was unconscious and
suffering from multiple organ failure, which required mechanical ventilation,
continuous dialysis and the administration of vasopressor medications.
The patient's viral load prior to the
administration of a single 6.5-hour Hemopurifier® treatment was measured
400,000 virus copies per milliliter of blood (copies/ml). Post-treatment viral load
was measured at 1,000 copies/ml and never again rose above that level. The
treatment was well tolerated with no adverse events reported.
Since the administration of Hemopurifier®
therapy, Frankfurt University Hospital officials have reported that Ebola virus
is no longer detectable in the patient's blood and full recovery is expected.
"The rate of viral load reduction and
magnitude of Ebola virus captured within the Hemopurifier® is quite remarkable
when considering the lethality of Ebola infection and the compromised health of
the patient," stated James A. Joyce, Chairman and CEO of Aethlon Medical.
"We're thrilled for the patient and applaud the tireless effort of
physicians in Frankfurt who helped to save the patient's life. We will continue
to advance Hemopurifier® therapy as a lead candidate to address antiviral drug
resistance and the sole broad-spectrum strategy to address Ebola other viruses
where drugs and vaccines have not proven to be effective."
Aethlon will soon begin the first U.S.
clinical Hemopurifier® studies following the United States Food and Drug
Administration's (FDA)'s approval of an Investigational Device Exemption (IDE).
The study will contribute safety data to advance the device as a broad-spectrum
countermeasure against pandemic threats, including Ebola and chronic viral
pathogens such as HIV and Hepatitis C (HCV).
Read this release
in full at: http://www.investorideas.com/CO/AEMD/news/2014/11141.asp
About Aethlon Medical, Inc.
Aethlon Medical creates targeted
therapeutic devices to address infectious disease, cancer and neurodegenerative
disorders. The company's lead product is the Aethlon Hemopurifier®, a
first-in-class antiviral and immunotherapeutic device that selectively targets
the broad-spectrum elimination of circulating viruses and tumor-secreted
exosomes that promote cancer progression. Exosome Sciences, Inc. is a majority
owned subsidiary that is advancing exosome-based products to diagnose and
monitor cancer, infectious disease and neurological disorders. For more
information, please visit http://www.aethlonmedical.com and connect with
the Company on Twitter, LinkedIn, Facebook and Google+.
Contacts:
Sign up
for the free investor news and stock alerts:
Disclaimer/Disclosure: The Investorideas.com newswire is a third party
publisher of news and research as well as creates original content as a news
source. Original content created by investorideas is protected by copyright
laws other than syndication rights. Investorideas is a news source on Google
news and Linkedintoday plus hundreds of syndication partners. Our site does not
make recommendations for purchases or sale of stocks or products. Nothing on
our sites should be construed as an offer or solicitation to buy or sell
products or securities. All investment involves risk and possible loss of
investment. This site is currently compensated by featured companies, news submissions,
content marketing and online advertising. Contact each company directly for
press release questions. Disclosure is posted on each release if required but
otherwise the news was not compensated for and is published for the sole
interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
Disclosure:
AEMD subscribes to the Investorideas newswire content publishing annual program
(9700 per Year, paid quarterly) for news publishing.
BC
Residents and Investor Disclaimer: Effective September 15 2008 - all BC
investors should review all OTC and Pink sheet listed companies for adherence
in new disclosure filings and filing appropriate documents with Sedar. Read for
more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors
must adhere to regulations of each country.
Become an Investorideas.com Member and access our 14 online stock
directories 24/7 –biotech, defense, mining stocks, oil and gas stocks and
more...
